13th July 2022

Fujifilm integrates AI software to help identify bone trauma at POC (Point-of-Care)

Fujifilm partners with GLEAMER – a medical technology company – to integrate artificial intelligence into its world-class X-ray imaging systems.

BoneView® is a revolutionary AI software designed to assist radiologists and emergency clinicians in the diagnosis of skeletal fractures. It uses advanced algorithms to detect and localise lesions on X-rays – graphically highlighting areas of interest – before submitting the images to radiologists for validation. Fujifilm X-ray systems are equipped with a new image processing box called EX-Mobile enabling to connect with BoneView® software. Results are available within 30 seconds at the point of care, providing healthcare professionals with additional support to help improve patient management.

The user-friendly software can be seamlessly integrated into Fujifilm’s comprehensive x-ray modality line-up, making it perfectly suited to small or remote clinics, pop-up medical centres, nursing homes, up to large multi-function institutions. This will aid medical staff in the rapid identification of patients with suspected fractures, triaging them for further investigation to ease workflows and enhance patient care pathways. A clinical trial involving appendicular skeletal fractures found that BoneView® reduced the number of false positives by 41.9 %, and improved fracture detection sensitivity and specificity.1 These results are supported by another study involving additional anatomical locations, where AI assistance reduced radiograph reading times by 6.3 seconds per patient.2

Richard Cahalane, Product Manager Digital Modalities, FUJIFILM Europe GmbH, explained: “It is very exciting to be part of this partnership. BoneView® is an extraordinary tool that will assist busy radiographers, radiologists and clinicians to better manage patients at the point of care, adding value for both staff and the patients.”

Christian Allouche, CEO at GLEAMER, added: “Having Fujifilm on board has been crucial in the development of this product, and to get it in front of the clinicians that need it. AI technologies are becoming increasingly established in the medical sector, and really proving their value. Any medical innovation is about improving the care of the patient, and BoneView® promises to do just that.”

BoneView® will be launched in Europe at the European Congress of Radiology in July.
Visit www.gleamer.ai/boneview for more information.

® BoneView is a trade mark of GLEAMER

References
1. Duron L, Ducarouge A, Gillibert A, et al. Assessment of an AI Aid in Detection of Adult Appendicular Skeletal Fractures by Emergency Physicians and Radiologists: A Multicenter Cross-sectional Diagnostic Study. Radiology. 2021;300(1):120-129. doi:10.1148/radiol.2021203886
2. Guermazi A, Tannoury C, Kompel AJ, et al. Improving Radiographic Fracture Recognition Performance and Efficiency Using Artificial Intelligence. Radiology. 2022;302(3):627-636. doi:10.1148/radiol.210937

About Fujifilm in Europe
Fujifilm operates over 50 group companies and branches in Europe and employs more than 6000 people engaged in R&D, manufacturing, sales and service, with FUJIFILM Europe GmbH, located in Ratingen, Germany, operating as the strategic headquarters for the region. Throughout Europe, Fujifilm entities serve a range of industries including medical technology, biopharmaceuticals, electronic materials, industrial products, chemicals, graphic systems, optical devices, data storage and all aspects of photography. Over the last 20 years, the company has more intensively focused on healthcare – from diagnosis to prevention and treatment. Today, Fujifilm in Europe provides the entire spectrum of patient care, in addition to research, development and manufacturing in advanced therapies, gene therapies and vaccines, as well as providing cell culture media and regenerative medicine solutions.
For more information, please visit: fujifilm.com

About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, located in Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2022, the company had global revenues of Euro 19,28 billion, at an exchange rate of 131 yen to the Euro. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.
For more information, please visit: holdings.fujifilm.com